Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 32: 2187-2190, 1986;
This Article
Right arrow Order Full text via Infotrieve
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by el-Yazigi, A.
Right arrow Articles by Al-Mefty, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by el-Yazigi, A.
Right arrow Articles by Al-Mefty, O.

Clinical Chemistry, Vol 32, 2187-2190, Copyright © 1986 by American Association for Clinical Chemistry

Concentrations of zinc, iron, molybdenum, arsenic, and lithium in cerebrospinal fluid of patients with brain tumors

A el-Yazigi, I Al-Saleh and O Al-Mefty

We used flameless atomic absorption spectrophotometry to measure concentrations of Fe, Mo, Li, As, and Zn in cerebrospinal fluid (CSF) of patients with malignant brain tumors benign brain tumors, non-brain malignant tumors and control (non-neoplastic disease) patients. Mean (and SD) concentrations (microgram/L) of these elements in the control group were 62.7 (28.7) for Fe, 6.8 (4.8) for Mo, 0.7 (2.0) for Li, 1.3 (0.7) for As, 7 (5.9) for Zn. We could detect Li in less than 53% of controls. Zn concentrations in CSF of patients with astrocytoma (malignant brain tumor), benign brain tumors, or non-brain tumors were significantly (p less than 0.05) less than in control patients; the ratios for mean concentrations of Zn in tumor patients/control patients for the above groups were 0.3, 0.20, and 0.17, respectively. Concentrations of As in CSF of patients with non-brain malignant tumors were significantly (p less than 0.05) higher than in the controls; the ratio for mean CSF concentration of As in patients with non-brain tumors/control patients was 2.9. Differences in the concentrations of Fe, Li, or Mo among the various groups were nonsignificant.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.